OTCMKTS:CPMV Mosaic ImmunoEngineering 8/14/2024 Earnings Report $0.49 -0.06 (-10.95%) As of 05/23/2025 02:21 PM Eastern ProfileEarnings History Mosaic ImmunoEngineering EPS ResultsActual EPS-$0.04Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMosaic ImmunoEngineering Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMosaic ImmunoEngineering Announcement DetailsQuarterDate8/14/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsMosaic ImmunoEngineering's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Mosaic ImmunoEngineering Earnings HeadlinesMosaic ImmunoEngineering, Inc. (CPMV)November 17, 2024 | finance.yahoo.comMosaic Co.November 5, 2024 | wsj.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 24, 2025 | Porter & Company (Ad)Mosaic ImmunoEngineering (OTC:CPMV) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comCowpea Mosaic Virus Nanoparticles Show Promise in Preventing Metastatic CancersMay 14, 2024 | msn.comNanoparticle plant virus treatment shows promise in fighting metastatic cancers in miceMay 13, 2024 | msn.comSee More Mosaic ImmunoEngineering Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mosaic ImmunoEngineering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mosaic ImmunoEngineering and other key companies, straight to your email. Email Address About Mosaic ImmunoEngineeringMosaic ImmunoEngineering (OTCMKTS:CPMV), a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.View Mosaic ImmunoEngineering ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout? Upcoming Earnings PDD (5/27/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Haleon (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
